$URGN
UroGen Pharma Ltd. Stock $urgn

$urgn Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000143774922026727 Filed on November 10, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$18.09M	$16.10M	$11.35M
YoY Change	11.86%	41.81%	227.97%
Cost Of Revenue	$2.263M	$2.020M	$1.244M
YoY Change	42.42%	62.38%	302.59%
Gross Profit	$15.83M	$14.08M	$10.11M
YoY Change	8.53%	39.28%	220.65%
Gross Profit Margin	87.49%	87.45%	89.04%
Selling, General & Admin	$21.63M	$19.07M	$21.62M
YoY Change	1.01%	-11.81%	-2.0%
% of Gross Profit	136.67%	135.48%	213.95%
Research & Development	$14.48M	$13.09M	$11.92M
YoY Change	10.66%	9.81%	16.77%
% of Gross Profit	91.46%	93.01%	117.97%
Depreciation & Amortization	$236.0K	$200.0K	$200.0K
YoY Change	10.8%	0.0%	100.0%
% of Gross Profit	1.49%	1.42%	1.98%
Operating Expenses	$36.11M	$32.16M	$33.55M
YoY Change	4.67%	-4.12%	3.94%
Operating Profit	-$20.28M	-$18.09M	-$23.44M
YoY Change	1.84%	-22.84%	-19.52%
Interest Expense	-$2.817M	-$2.253M	$73.00K
YoY Change	-14185.0%	-3186.3%	-81.28%
% of Operating Profit
Other Income/Expense, Net	-$5.081M	-$4.782M	-$6.844M
YoY Change	-31.52%	-30.13%	8455.0%
Pretax Income	-$28.18M	-$25.12M	-$30.21M
YoY Change	3.17%	-16.84%	4.84%
Income Tax	$69.00K	$709.0K	$0.00
% Of Pretax Income
Net Earnings	-$28.25M	-$25.83M	-$30.21M
YoY Change	-0.71%	-14.5%	4.84%
Net Earnings / Revenue	-156.14%	-160.47%	-266.15%
Basic Earnings Per Share		-$1.13	-$1.35
Diluted Earnings Per Share	-$1.22	-$1.133M	-$1.350M
COMMON SHARES
Basic Shares Outstanding	23.09M	22.74M	22.38M
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$99.96M	$95.91M	$106.2M
YoY Change	12.14%	-9.7%	-11.2%
Cash & Equivalents	$55.41M	$28.69M	$55.34M
Short-Term Investments	$44.56M	$67.23M	$50.87M
Other Short-Term Assets	$11.91M	$11.39M	$7.339M
YoY Change	36.91%	55.23%	33.44%
Inventory	$4.325M	$4.862M	$3.808M
Prepaid Expenses
Receivables	$12.70M	$9.429M	$7.784M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$128.9M	$121.6M	$125.1M
YoY Change	12.69%	-2.83%	-3.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.297M	$1.519M	$1.978M
YoY Change	-34.06%	-23.21%	14.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00	$4.071M
YoY Change	-100.0%	-100.0%	-31.0%
Other Assets	$2.740M	$2.471M	$1.773M
YoY Change	109.0%	39.37%	491.0%
Total Long-Term Assets	$6.712M	$6.879M	$9.463M
YoY Change	25.32%	-27.31%	-10.73%
TOTAL ASSETS
Total Short-Term Assets	$128.9M	$121.6M	$125.1M
Total Long-Term Assets	$6.712M	$6.879M	$9.463M
Total Assets	$135.6M	$128.5M	$134.6M
YoY Change	13.26%	-4.55%	-3.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.527M	$2.545M	$4.060M
YoY Change	-4.48%	-37.32%	-1.79%
Accrued Expenses	$16.05M	$14.38M	$14.61M
YoY Change	11.85%	-1.61%	8.23%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$23.92M	$19.00M	$19.81M
YoY Change	6.86%	-4.07%	12.53%
LONG-TERM LIABILITIES
Long-Term Debt	$97.54M	$71.87M	$0.00
YoY Change
Other Long-Term Liabilities	$103.5M	$100.9M	$83.26M
YoY Change	16.38%	21.17%	4797.65%
Total Long-Term Liabilities	$97.54M	$71.87M	$83.26M
YoY Change		-13.68%	4797.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.92M	$19.00M	$19.81M
Total Long-Term Liabilities	$97.54M	$71.87M	$83.26M
Total Liabilities	$225.0M	$191.8M	$103.1M
YoY Change	102.08%	86.05%	431.27%
SHAREHOLDERS EQUITY
Retained Earnings	-$577.1M	-$548.2M	-$438.9M
YoY Change	23.5%	24.9%	34.63%
Common Stock	$487.9M	$485.1M	$470.4M
YoY Change	2.54%	3.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$89.36M	-$63.29M	$31.54M
YoY Change
Total Liabilities & Shareholders Equity	$135.6M	$128.5M	$134.6M
YoY Change	13.26%	-4.55%	-3.79%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$28.25M	-$25.83M	-$30.21M
YoY Change	-0.71%	-14.5%	4.84%
Depreciation, Depletion And Amortization	$236.0K	$200.0K	$200.0K
YoY Change	10.8%	0.0%	100.0%
Cash From Operating Activities	-$21.75M	-$17.61M	-$18.48M
YoY Change	8.38%	-4.68%	-26.33%
INVESTING ACTIVITIES
Capital Expenditures	$13.00K	-$153.0K	-$194.0K
YoY Change	-106.44%	-21.13%	-70.61%
Acquisitions
YoY Change
Other Investing Activities	$23.12M	-$35.34M	$10.85M
YoY Change	147.89%	-425.59%	-21.91%
Cash From Investing Activities	$23.11M	-$35.49M	$10.66M
YoY Change	153.24%	-432.95%	-19.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	25.37M	1.101M	-168.0K
YoY Change	-79375.0%	-755.36%	-380.0%
NET CHANGE
Cash From Operating Activities	-21.75M	-17.61M	-18.48M
Cash From Investing Activities	23.11M	-35.49M	10.66M
Cash From Financing Activities	25.37M	1.101M	-168.0K
Net Change In Cash	26.72M	-52.00M	-7.984M
YoY Change	-343.45%	551.35%	-32.28%
FREE CASH FLOW
Cash From Operating Activities	-$21.75M	-$17.61M	-$18.48M
Capital Expenditures	$13.00K	-$153.0K	-$194.0K
Free Cash Flow	-$21.76M	-$17.46M	-$18.28M
YoY Change	9.55%	-4.5%	-25.14%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23011324
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23011324
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22462995
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22462995
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-40913000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-99000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-25831000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	56271000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8413000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-80914000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	96355000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	61000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-82368000	usd
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000.0
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38079
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1460746
	dei	Entity Address Address Line1 EntityAddressAddressLine1	400 Alexander Park Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Princeton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08540
	dei	City Area Code CityAreaCode	646
	dei	Local Phone Number LocalPhoneNumber	768-9780
	dei	Security12b Title Security12bTitle	Ordinary Shares, par value NIS 0.01 per share
	dei	Trading Symbol TradingSymbol	URGN
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23090039
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28686000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44360000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	67225000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	44779000	usd
CY2022Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	812000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1226000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9429000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11717000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	4862000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4832000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10580000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7476000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	121594000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	114390000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1519000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1967000	usd
CY2022Q3	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	223000	usd
CY2021Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	223000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2666000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1180000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	675000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2471000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1311000	usd
CY2022Q3	us-gaap	Assets Assets	128473000	usd
CY2021Q4	us-gaap	Assets Assets	119746000	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9356000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	12102000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6625000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6948000	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3018000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3330000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	18999000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22380000	usd
CY2022Q3	urgn	Prepaid Forward Obligation PrepaidForwardObligation	96192000	usd
CY2021Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	85713000	usd
CY2022Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	71870000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1856000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	398000	usd
CY2022Q3	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	2842000	usd
CY2021Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	2842000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	191759000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	111333000	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	63000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	61000	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	485041000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	475698000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-548235000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-467321000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-155000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-25000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-63286000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	8413000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	128473000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	119746000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16097000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11351000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	46265000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31868000	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	2020000	usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	1244000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	5391000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	3568000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	14077000	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	10107000	usd
	us-gaap	Gross Profit GrossProfit	40874000	usd
	us-gaap	Gross Profit GrossProfit	28300000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13093000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11923000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	38429000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34560000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19071000	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21624000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	61204000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	66117000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18087000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-23440000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-58759000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-72377000	usd
CY2022Q3	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	4819000	usd
CY2021Q3	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	6828000	usd
	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	16478000	usd
	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	9948000	usd
CY2022Q3	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	2694000	usd
CY2021Q3	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	-0	usd
	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	5215000	usd
	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	-0	usd
CY2022Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	478000	usd
CY2021Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	57000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	604000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	269000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25122000	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-30211000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-79848000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-82056000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	709000	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1066000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	312000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-25831000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-30211000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-80914000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-82368000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-25831000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-30211000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-80914000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-82368000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-99000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-41000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-130000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-267000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25930000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30252000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-81044000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-82635000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.13
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.35
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.56
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.69
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22798263
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22380598
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22711686
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22318589
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2440000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-63286000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5515000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-41000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-30211000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	31537000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8212000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-130000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-63286000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17756000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-267000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	31537000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-80914000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-82368000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	688000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	618000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	17756000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1077000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	679000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	704000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	615000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
	urgn	Accrued Financing On Prepaid Forward Obligation AccruedFinancingOnPrepaidForwardObligation	11019000	usd
	urgn	Accrued Financing On Prepaid Forward Obligation AccruedFinancingOnPrepaidForwardObligation	8583000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	93000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-343000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	8212000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	645000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1844000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2288000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	737000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3104000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2749000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1000000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1573000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2746000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1032000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-323000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-3078000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-704000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-595000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-856000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-914000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-65807000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-64822000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	63009000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	51594000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	2463000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	41202000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	44625000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	241000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	550000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22048000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5056000	usd
	urgn	Proceeds From Prepaid Forward Arrangement Net ProceedsFromPrepaidForwardArrangementNet	0	usd
	urgn	Proceeds From Prepaid Forward Arrangement Net ProceedsFromPrepaidForwardArrangementNet	72417000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1133000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	61000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	70793000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	160000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	127000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	71766000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	72351000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16089000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2473000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	45587000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	54090000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	29498000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	56563000	usd
	urgn	Non Cash New Lease Liabilities NonCashNewLeaseLiabilities	2165000	usd
	urgn	Non Cash New Lease Liabilities NonCashNewLeaseLiabilities	-36000	usd
	urgn	Issuance Costs Incurred During Noncash Or Partial Noncash Transaction IssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	usd
	urgn	Issuance Costs Incurred During Noncash Or Partial Noncash Transaction IssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	7000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">1</em> </b>–<b> Business and Nature of Operations</b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Nature of Operations</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma Ltd. is an Israeli company incorporated in <em style="font: inherit;"> April 2004 (</em>“UPL”).</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UroGen Pharma Inc., a wholly owned subsidiary of UPL, was incorporated in Delaware in <em style="font: inherit;"> October 2015 </em>and began operating in <em style="font: inherit;"> February 2016 (</em>“UPI”).</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UPL and UPI (together the “Company”) is a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, launching the Company’s <em style="font: inherit;">first</em> commercial product, <i>Jelmyto</i> (mitomycin) for pyelocalyceal solution, formerly known as UGN-<em style="font: inherit;">101,</em> clinical development of UGN-<em style="font: inherit;">102,</em> and raising capital to support and expand these activities.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> April 15, 2020, </em>the U.S. Food and Drug Administration (“FDA”) granted expedited approval for <i>Jelmyto</i>, a <em style="font: inherit;">first</em>-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (“low-grade UTUC”). <i>Jelmyto</i> consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release RTGel technology. It has been designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means.</p>
	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note <em style="font: inherit;">2</em> </b>–<b> Basis of Presentation</b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the instructions to Form <em style="font: inherit;">10</em>-Q and Article <em style="font: inherit;">10</em> of Regulation S-<em style="font: inherit;">X.</em> Accordingly, they do <em style="font: inherit;">not</em> include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for fair statement of its financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. Interim results are <em style="font: inherit;">not</em> necessarily indicative of results for the full fiscal year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does <em style="font: inherit;">not</em> include all disclosures required by accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in the Company’s Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> as filed with the Securities and Exchange Commission (“SEC”) on <em style="font: inherit;"> March 21, 2022.</em></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company has experienced net losses since its inception and has an accumulated deficit o<span style="background-color:#ffffff;">f $548.2 </span>million and $467.3 million as of <em style="font: inherit;"> September 30, 2022</em> and <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it executes on its strategy including engaging in further research and development activities, particularly conducting non-clinical studies and clinical trials.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The success of the Company depends on the ability to successfully commercialize its technologies to support its operations and strategic plan. Based on management’s cash flow projections the Company believes that its cash and cash equivalents and marketable securities are sufficient to fund the Company’s planned operations for at least the next <em style="font: inherit;">12</em> months. The Company anticipates that it will need to raise additional capital in the future. There can be <em style="font: inherit;">no</em> assurances that the Company will be able to secure such additional financing if at all, or on terms that are satisfactory to the Company, and that it will be sufficient to meet its needs. In the event the Company is <em style="font: inherit;">not</em> successful in obtaining sufficient funding, this could force us to delay, limit, or reduce our product development, commercialization efforts or other operations.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p>
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-548200000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-467300000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results <em style="font: inherit;"> may </em>differ from those estimates. As applicable to the unaudited condensed consolidated financial statements, the critical accounting estimates relate to the fair value of share-based compensation, measurement of revenue, estimate of uncertain tax positions, and measurement of liabilities accounted for under the interest method.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p>
CY2022Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	95900000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Concentration of Credit Risk</i></b></p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does <em style="font: inherit;">not</em> enter into any investment transaction for trading or speculative purposes.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company’s product sales are recognized through the Company's arrangement with a single customer, a <em style="font: inherit;">third</em>-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has <em style="font: inherit;">not</em> experienced any credit losses related to this customer and has <em style="font: inherit;">not</em> currently recognized any allowance for doubtful accounts.</p> <p style="font-family: Arial, Helvetica, sans-serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p>
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2545000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5786000	usd
CY2022Q3	urgn	Accrued Sales Reserve Current AccruedSalesReserveCurrent	687000	usd
CY2021Q4	urgn	Accrued Sales Reserve Current AccruedSalesReserveCurrent	497000	usd
CY2022Q3	urgn	Accrued Clinical Expense AccruedClinicalExpense	2285000	usd
CY2021Q4	urgn	Accrued Clinical Expense AccruedClinicalExpense	1377000	usd
CY2022Q3	urgn	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	1118000	usd
CY2021Q4	urgn	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	1748000	usd
CY2022Q3	urgn	Accrued Selling General And Administrative Expense AccruedSellingGeneralAndAdministrativeExpense	2139000	usd
CY2021Q4	urgn	Accrued Selling General And Administrative Expense AccruedSellingGeneralAndAdministrativeExpense	1965000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	582000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	729000	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9356000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	12102000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	469000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	345000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	135000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-76000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	604000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	269000	usd
CY2022Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5100000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3894000	usd
CY2022Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1863000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1958000	usd
CY2022Q3	urgn	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	6963000	usd
CY2021Q4	urgn	Inventory Current And Noncurrent Net InventoryCurrentAndNoncurrentNet	5852000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	67380000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	155000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	67225000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	64900000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	67225000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	44779000	usd
CY2022Q3	urgn	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	0	usd
CY2021Q4	urgn	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree	675000	usd
CY2022Q3	us-gaap	Investments Investments	67225000	usd
CY2021Q4	us-gaap	Investments Investments	45454000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4433000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4193000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2914000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2226000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1519000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1967000	usd
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	700000	usd
CY2021Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	600000	usd
CY2020Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	75000000	usd
CY2021	urgn	Capitalized Closing Costs On Prepaid Forward Obligation CapitalizedClosingCostsOnPrepaidForwardObligation	2599000	usd
CY2021	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	17291000	usd
CY2021	urgn	Decrease In Prepaid Forward Obligation Amounts Paid And Payable DecreaseInPrepaidForwardObligationAmountsPaidAndPayable	3979000	usd
CY2021Q4	urgn	Prepaid Forward Obligation PrepaidForwardObligation	85713000	usd
	urgn	Financing On Prepaid Forward Obligation FinancingOnPrepaidForwardObligation	16478000	usd
	urgn	Decrease In Prepaid Forward Obligation Amounts Paid And Payable DecreaseInPrepaidForwardObligationAmountsPaidAndPayable	5999000	usd
CY2022Q3	urgn	Prepaid Forward Obligation PrepaidForwardObligation	96192000	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	219000	usd
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	259000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	735000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	786000	usd
CY2022Q3	us-gaap	Sublease Income SubleaseIncome	56000	usd
CY2021Q3	us-gaap	Sublease Income SubleaseIncome	56000	usd
	us-gaap	Sublease Income SubleaseIncome	168000	usd
	us-gaap	Sublease Income SubleaseIncome	168000	usd
CY2022Q3	us-gaap	Variable Lease Cost VariableLeaseCost	16000	usd
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	15000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	52000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	51000	usd
CY2022Q3	us-gaap	Lease Cost LeaseCost	179000	usd
CY2021Q3	us-gaap	Lease Cost LeaseCost	218000	usd
	us-gaap	Lease Cost LeaseCost	619000	usd
	us-gaap	Lease Cost LeaseCost	669000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2666000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1180000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1856000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	398000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	3926000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	2734000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2606000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	135000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y11M12D
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M4D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1021	pure
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0551	pure
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	300000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1161000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	918000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	799000	usd
CY2022Q3	urgn	Lessee Operating Lease Liability To Be Paid After Year Three LesseeOperatingLeaseLiabilityToBePaidAfterYearThree	49000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3227000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	431000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2796000	usd
CY2022Q3	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	61000	usd
CY2022Q3	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	251000	usd
CY2022Q3	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	49000	usd
CY2022Q3	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	0	usd
CY2022Q3	urgn	Lessor Operating Lease Payment To Be Received After Year Three LessorOperatingLeasePaymentToBeReceivedAfterYearThree	0	usd
CY2022Q3	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	361000	usd
CY2022Q3	us-gaap	Sublease Income SubleaseIncome	56000	usd
CY2021Q3	us-gaap	Sublease Income SubleaseIncome	56000	usd
	us-gaap	Sublease Income SubleaseIncome	168000	usd
	us-gaap	Sublease Income SubleaseIncome	168000	usd
CY2021Q4	urgn	Accrued Sales Reserve AccruedSalesReserve	1708000	usd
	urgn	Sales Reserve Accruals SalesReserveAccruals	8842000	usd
	urgn	Sales Reserve Utilization SalesReserveUtilization	-8225000	usd
CY2022Q3	urgn	Accrued Sales Reserve AccruedSalesReserve	2325000	usd
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000.0
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23000000.0
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22500000
CY2022Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3442209
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1601242
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2440000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5515000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8212000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17756000	usd
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	12200000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y8M1D
CY2022Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2800000	usd
CY2022Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	900000	usd

Files In Submission

Name	View Source	Status
0001437749-22-026727-index-headers.html	Edgar Link	pending
0001437749-22-026727-index.html	Edgar Link	pending
0001437749-22-026727.txt	Edgar Link	pending
0001437749-22-026727-xbrl.zip	Edgar Link	pending
ex_418761.htm	Edgar Link	pending
ex_418762.htm	Edgar Link	pending
ex_418763.htm	Edgar Link	pending
ex_418764.htm	Edgar Link	pending
ex_443657.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
urgn-20220930.xsd	Edgar Link	pending
urgn20220930_10q.htm	Edgar Link	pending
urgn-20220930_cal.xml	Edgar Link	unprocessable
urgn-20220930_pre.xml	Edgar Link	unprocessable
urgn-20220930_lab.xml	Edgar Link	unprocessable
urgn-20220930_def.xml	Edgar Link	unprocessable
urgn20220930_10q_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$URGN
UroGen Pharma Ltd. Stock $urgn

2022 Q4 Form 10-Q Financial Statement

#000143774922026727 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$URGN UroGen Pharma Ltd. Stock $urgn

2022 Q4 Form 10-Q Financial Statement

#000143774922026727 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$URGN
UroGen Pharma Ltd. Stock $urgn